Browse by author
Lookup NU author(s): Stuart Ferguson,
Dr Gordon Strathdee
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background. The HLXB9 gene encodes a homeodomain containing transcription factor which has been implicated in the development of both solid and hematological malignancies. In leukemia it is one of the two fused genes, along with ETV6, in a recurrent translocation frequently observed in infant AML. Procedure. Here we investigate the role of epigenetic inactivation of the HLXB9 gene in leukemia. Quantitative DNA methylation analysis was performed using the COBRA assay, and qRT-PCR was used to assess the effects of methylation on expression in hematological cell lines and primary ALL samples. Results. Hypermethylation of the HLXB9 gene was found to be a frequent event in childhood ALL, occurring in 33% of cases. However, it was rarely or never observed in other types of leukemia, including AML, CML, and CLL, with the exception of adult ALL, in which 39% of cases were hypermethylated. Furthermore, hypermethylation of HLXB9 results in loss of expression in hematological cell lines and primary ALL samples. Conclusion. These results suggest that HLXB9 may have a dual role in childhood leukemia, as an oncogene in infant AML but as a tumor suppressor in childhood ALL. Pediatr Blood Cancer 2011;56:349-352. (C) 2010 Wiley-Liss, Inc.
Author(s): Ferguson S, Gautrey HE, Strathdee G
Publication type: Article
Publication status: Published
Journal: Pediatric Blood & Cancer
Print publication date: 10/11/2010
ISSN (print): 1545-5009
ISSN (electronic): 1545-5017
Publisher: John Wiley & Sons, Inc.
Altmetrics provided by Altmetric